Latest filings (excl ownership)
8-K
Unregistered Sales of Equity Securities
25 Apr 24
S-1
IPO registration
18 Apr 24
ARS
2023 FY
Annual report to shareholders
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
POS AM
Prospectus update (post-effective amendment)
26 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
424B3
Prospectus supplement
18 Mar 24
8-K
Spyre Therapeutics Announces $180 Million Private Placement
18 Mar 24
POS AM
Prospectus update (post-effective amendment)
14 Mar 24
S-1/A
IPO registration (amended)
14 Mar 24
POS AM
Prospectus update (post-effective amendment)
5 Mar 24
S-1/A
IPO registration (amended)
1 Mar 24
S-8
Registration of securities for employees
29 Feb 24
8-K
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
424B3
Prospectus supplement
6 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Jan 24
D
$180.00 mm in equity, sold $180.00 mm, 30 investors
26 Dec 23
S-8
Registration of securities for employees
22 Dec 23
S-1
IPO registration
22 Dec 23
424B3
Prospectus supplement
8 Dec 23
8-K
Spyre Therapeutics Announces $180 Million Private Placement
8 Dec 23
424B3
Prospectus supplement
30 Nov 23
8-K
Appoints CEO and Additional Directors, and Expands Leadership Team to
28 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
S-1/A
IPO registration (amended)
15 Nov 23
8-K
Other Events
15 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
DEF 14A
Definitive proxy
26 Oct 23
CORRESP
Correspondence with SEC
26 Oct 23
8-K
Regulation FD Disclosure
24 Oct 23
Latest ownership filings
4
Peter Evan Harwin
25 Apr 24
SC 13D/A
Fairmount Funds Management LLC
25 Apr 24
SC 13G/A
Avoro Capital Advisors LLC
23 Apr 24
SC 13G/A
FMR LLC
11 Mar 24
4
Cameron Turtle
20 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
Logos Global Management LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
BCLS II Equity Opportunities, LP
13 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Affinity Asset Advisors, LLC
13 Feb 24
SC 13G/A
Polar Capital Holdings Plc
13 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G
FMR LLC
9 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
8 Feb 24
4
Mark C. McKenna
5 Feb 24
3
Mark C. McKenna
5 Feb 24
4
Cameron Turtle
2 Feb 24
4
Scott L Burrows
2 Feb 24
4
Heidy King-Jones
2 Feb 24
SC 13D/A
Fairmount Funds Management LLC
29 Dec 23
4
Peter Evan Harwin
29 Dec 23
4
Scott L Burrows
22 Dec 23
SC 13G
PERCEPTIVE ADVISORS LLC
13 Dec 23
4
Peter Evan Harwin
11 Dec 23
SC 13D/A
Fairmount Funds Management LLC
11 Dec 23
4/A
Jeffrey W. Albers
8 Dec 23
3/A
Jeffrey W. Albers
8 Dec 23
SC 13G
COMMODORE CAPITAL LP
1 Dec 23
SC 13D/A
Fairmount Funds Management LLC
29 Nov 23
4
Peter Evan Harwin
28 Nov 23
4
Jeffrey W. Albers
27 Nov 23